The stock of Insmed Incorporated (NASDAQ:INSM) is a huge mover today! The stock increased 4.46% or $0.65 during the last trading session, hitting $15.22. About 278,929 shares traded hands. Insmed Incorporated (NASDAQ:INSM) has risen 2.17% since April 22, 2016 and is uptrending. It has underperformed by 3.24% the S&P500.
The move comes after 8 months positive chart setup for the $965.64M company. It was reported on Nov, 25 by Barchart.com. We have $16.29 PT which if reached, will make NASDAQ:INSM worth $67.59 million more.
Analysts await Insmed Incorporated (NASDAQ:INSM) to report earnings on February, 23. They expect $-0.99 earnings per share, down 94.12% or $0.48 from last year’s $-0.51 per share. After $-0.61 actual earnings per share reported by Insmed Incorporated for the previous quarter, Wall Street now forecasts 62.30% negative EPS growth.
Insmed Incorporated (NASDAQ:INSM) Ratings Coverage
Out of 6 analysts covering Insmed (NASDAQ:INSM), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. Insmed has been the topic of 8 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Zacks upgraded Insmed Incorporated (NASDAQ:INSM) rating on Thursday, August 20. Zacks has “Hold” rating and $28 price target. The rating was downgraded by UBS on Monday, November 9 to “Neutral”. Zacks downgraded Insmed Incorporated (NASDAQ:INSM) on Monday, August 10 to “Hold” rating. The firm has “Neutral” rating given on Wednesday, March 16 by Citigroup. Stifel Nicolaus initiated the shares of INSM in a report on Tuesday, March 15 with “Buy” rating. The company was upgraded on Friday, September 4 by Zacks. The company was maintained on Tuesday, October 6 by H.C. Wainwright.
According to Zacks Investment Research, “Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company’s inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.”
Insitutional Activity: The institutional sentiment decreased to 1.15 in 2016 Q2. Its down 0.50, from 1.65 in 2016Q1. The ratio turned negative, as 11 funds sold all Insmed Incorporated shares owned while 23 reduced positions. 17 funds bought stakes while 39 increased positions. They now own 55.48 million shares or 0.92% less from 56.00 million shares in 2016Q1.
Highbridge Limited last reported 0.01% of its portfolio in the stock. Ridgeworth Cap Management Limited Liability Com owns 29,843 shares or 0% of their US portfolio. Pictet Asset Mgmt accumulated 0% or 49,543 shares. Td Asset Inc accumulated 0% or 238,400 shares. Secor Cap Advsrs Lp, a New York-based fund reported 82,799 shares. Acuta Limited Liability Company has invested 1.04% of its portfolio in Insmed Incorporated (NASDAQ:INSM). Voya Investment Mngmt Lc holds 0% or 25,571 shares in its portfolio. Blackrock Gp Ltd, a United Kingdom-based fund reported 25,673 shares. Amer International Grp Incorporated reported 35,648 shares or 0% of all its holdings. Diam Comm Ltd has 281,674 shares for 0.04% of their US portfolio. Renaissance Technology Ltd Co accumulated 149,300 shares or 0% of the stock. The Colorado-based Janus Mgmt Ltd Llc has invested 0.02% in Insmed Incorporated (NASDAQ:INSM). State Street owns 1.36 million shares or 0% of their US portfolio. Clearbridge Invs Limited Liability Corporation last reported 0% of its portfolio in the stock. The Pennsylvania-based Susquehanna Intll Group Ltd Liability Partnership has invested 0% in Insmed Incorporated (NASDAQ:INSM).
Insider Transactions: Since November 7, 2016, the stock had 0 insider buys, and 2 insider sales for $1.48 million net activity. Another trade for 68,774 shares valued at $821,931 was made by Schaeffer Orlov S Nicole on Monday, November 7. On Monday, November 14 the insider Drechsler Andrew T sold $660,150.
More important recent Insmed Incorporated (NASDAQ:INSM) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on December 21, 2009, also Quotes.Wsj.com published article titled: “News Insmed Inc.INSM”, Fool.com published: “Why Insmed Incorporated Shares Skyrocketed” on June 18, 2014. More interesting news about Insmed Incorporated (NASDAQ:INSM) was released by: Globenewswire.com and their article: “EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action …” with publication date: August 12, 2016.
INSM Company Profile
Insmed Incorporated, incorporated on March 21, 2013, is a biopharmaceutical company. The Firm operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.